

How a new killer flu could turn you into a **millionaire**

My #1 Biotech Stock Pick of the Year

I've discovered an emerging biotech with FDA APPROVAL on their patented technology that obliterates infectious airborne bacteria with 99.9% effectiveness.

It's the first revolutionary breakthrough in 70 years!
Story starts on page 2...



Buy UVFT Today.
370% gains projected!

Contact UV Flu Technologies Today!
Visit www.ndm1flu.com
or Call Investor Relations at 1-888-355-8838


#1 Biotech Stock Pick of 2010

 Michael Williams
MARKET MOVERS

Urgent Biotech Report

Fall 2010 | Complimentary Issue

 U.S. Food and Drug Administration
Certifies Technology That Could Have Investors Seeing
370% Gains in Just Weeks!



Find Out More About the Next Big Pick from America's Authority on Small-Cap Biotech Stocks

 Michael Williams
MARKET MOVERS

MS Corporate Communications
1230 Avenue of the Americas
7th Floor
New York, NY 10020

*"I am convinced UVFT is my new Big Money Winner!
With UVFT in your portfolio, you could turn \$5,000 into \$18,500
and \$10,000 could result in a gain of over \$37,000.
Do not hesitate. Buy UVFT Today!"*

*- Michael Williams
MW Market Movers*



Michael Williams
Publisher
Michael Williams Market Movers

Michael Williams is America's top authority on small-cap biotech stock picks. His winning picks include:

- BioPack Environmental (BPAC.OB): soared 430.77% since 2009
- Sun Cal Energy (SCEY.PK): skyrocketed 153.33% in a few weeks
- Bloggerwave (BLGW.OB): sailed 405% in just months



"UNDISCOVERED" Biotech Deal
Technology receives FDA Approval to market its bacteria-killing purification system as a medical device
Special Report begins on page 2

Michael's latest winning biotech pick is profiled inside this Special Report.
Story starts on page 2.

A Message from Michael Williams



Dear Profit Seeker,

Every few years or so, the “perfect” scenario unfolds for a particular investment. A company may have a great product, for example...and by investing in that company at a time when the market for

that product is poised to skyrocket... well, the potential exists for life-altering gains.

My name is Michael Williams, Editor of Market Movers, and it’s my job to uncover those overlooked and potentially “perfect” opportunities and show my readers how to exploit those situations.

Why settle for “boring” 10 - 20% returns?

There’s nothing wrong with earning a 10% or 20% return on a stock, but at Market Movers, modest profits don’t get our blood racing or our pulse pounding.

My subscribers and I are addicted to the thrill of home runs: buying a small, undiscovered company and watching its share price go through the roof! That’s why I think you will be interested in reading more about my current pick, UV Flu Technologies (UVFT), an emerging company that is about to become a major player in the biotech industry.

How do you separate the winners from the losers with biotech stocks? By remembering that winners outperform the market for five very specific reasons.

IT’S NEVER ACCIDENTAL.

Leadership.

We look at a company’s leadership. Are they experienced and have they proven their skills at other companies?

Earnings.

Are their future earnings robust, yet currently

priced well below (up to 80%) their fair value? Most of our stocks are either selling at a deep discount to their net current asset value, or their P/E is reasonably priced within the average range for their sector.

Business Plan.

Do they have a sound business plan? Without the right directions you can never get to where you’re going.

Market Trends.

Out of the few companies that get this far our team then looks over current political, economic and investment trends to make our final recommendations. Social, political and economic trends must be moving in the right direction. Investors must be confident that prices will be heading up, and as the enclosed report details, biotech has never been hotter - and demand is expected to continue soaring!


Investor Awareness.

Furthermore, ‘hot’ stocks are almost always actively marketed to investors - and everyone benefits because shares are like products: **THEY MUST BE SOLD.** Every biotech company should meet this standard - five out of five, nothing less. If a company is weak in even one area, it won’t make my pick list.

As you’ll see from the attached special report, UV Flu Technologies has a great story to tell - one of the best opportunities to come along in years, as a matter of fact - and they’ll be very

aggressive in making sure it gets wide distribution. (After all, what good is an up-and-coming investment if hardly anyone hears about it!!!)

I’d urge you to take a few minutes to learn more about this company, and further investigate its prospects with your broker or investment advisor.



Contact UV Flu Technologies Today!
 Visit www.ndm1flu.com
 or Call Investor Relations at 1-888-355-8838

UVFT could be well on its way to 370% gains!

Don't miss out on this opportunity.

The Biotech industry has historically outperformed the broad market. I am confident UVFT could outperform most emerging like-biotechs to deliver one of the best stock performances this year.

Call your broker or go online to invest in UVFT today. The earlier you get in, the lower the share price, the greater the gain you could see. Invest \$5,000 - \$10,000 in UV Flu Technologies (UVFT) today for potential 370% profit in the coming weeks!

Triple-digit gains could be yours, too, when you subscribe to Michael Williams Market Movers newsletter and advisory service. Right now I have a terrific offer for you with my...

BEST DEAL EVER!

Subscribe today for just \$99 - Save 50%!

Through this special new subscriber only offer, you can get a full year of Michael Williams Market Movers newsletter and advisory service, for just \$99! You save 50% off the regular subscription price of \$198.

Of course, you don’t even have to spend one dime to act on UV Flu Technologies (UVFT). I’m giving you my #1 biotech stock pick of the year today, just to show you the kind of fortune-making stocks I find for my readers.

All I ask is that, if you make a ton of money on UVFT in the next few weeks, then subscribe to my newsletter advisory service for more of the same.

With UVFT alone you could make \$18,500 on a \$5,000 investment and \$37,000 on a \$10,000 investment—more than enough to pay for a subscription over and over!

Subscribe today at www.mwmarketmovers.com

Here’s to market moving profits,

Michael Williams
 Editor, MW Market Movers

www.mwmarketmovers.com

Get advance information on tomorrow’s biggest stock winners like UVFT!

Build the investing fortune you’ve always wanted by getting information on tomorrow’s biggest stock winners today. That’s what’s helped lead my subscribers to gains such as:

- **A5 Laboratories Inc. (AFLB.OB)**, it soared from **\$0.78 to \$1.08 from Aug.26 2010 to Sept.2 2010, +38% average**
- **Arrowhead Research Corp. (ARWR)**, it rocketed from **\$1.09 to \$1.55 from Apr.5 2010 to Apr.29 2010, +42% average!**

If you want to know about the latest winning buys, simply subscribe to my newsletter,
Michael Williams Market Movers
Today.

Subscribe at www.mwmarketmovers.com

IMPORTANT NOTICE AND DISCLAIMER: Michael Williams Market Movers is an independent paid circulation newsletter. This paid advertising issue of Michael Williams Market Movers does not purport to provide an analysis of any company’s financial position or prospects and this is not to be construed as a recommendation by Michael Williams and/or Michael Williams Market Movers and is not in any way to be construed as an offer or solicitation to buy or sell any security. This stock was chosen to be profiled after Michael Williams Market Movers completed due diligence on the stock. Although the information contained in this advertisement is believed to be reliable, Michael Williams Market Movers, and its editors make no warranties as to the accuracy of the description of any of the content herein and accept no liability for how readers may choose to use it. Michael Williams and/or Michael Williams Market Movers, including any of our principals, officers, directors, partners, agents, or affiliates are not, nor do we represent ourselves to be, registered investment advisors, brokers, or dealers in securities. Readers should independently verify all statements made in this advertisement. Product names, logos, brands, and other trademarks featured or referred to within this advertisement are the property of their respective trademark holders. These trademark holders are not affiliated with Michael Williams Market Movers.

This advertisement, and the opinions of those quoted within are for informational and advertising purposes only. Speculation in securities carries a high degree of risk and investors purchasing speculative investments should be capable of absorbing losses of all of their invested capital. There is no assurance that the featured company will receive additional funding or experience any future development necessary for corporate success. Information contained in this advertisement contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the expected continual growth of the market for the company’s products, the company’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.

Past investment performance is not in any way indicative of future investment performance. Readers must consult with registered professional investment, taxation, and portfolio advisors before making an investment decision. This advertisement is a solicitation for subscriptions. UV Flu Technologies Inc. (hereafter “UV”), the company featured in this report, appears as paid advertising, paid by Cosworth Communications Limited (a non-affiliated third-party). UV has neither approved nor paid for this specific advertisement. Michael Williams Market Movers received a Twenty Four Thousand dollar editorial fee from Cosworth Communications Limited, to cover editorial costs associated with the development of this advertising report. Michael Williams Market Movers stands to make a profit from the editorial services charged. Michael Williams Market Movers expects to generate new subscriber revenue, the amount of which is unknown at this time, to its online newsletter through the distribution of this advertisement. As of the date this advertisement was produced, Cosworth Communications Limited has paid Five Hundred Thousand Dollars to various marketing, promotion, and advertising vendors, for all the costs of creating, producing, and distributing this report and other materials related to UV in an effort to build investor awareness. Please visit <http://www.mwmarketmovers.com/disclaimer.asp> to read our full disclaimer. This is not intended for readers in any jurisdiction where not permissible under local regulations and investors in those jurisdictions should disregard the content and any information from Michael Williams Market Movers. Readers and members must also independently verify the “blue-sky” eligibility of any securities mentioned within this email or special report. Further, specific financial information, filings and disclosures as well as general investor information about publicly listed companies and other investor resources can be found at Securities and Exchange Commission website at www.sec.gov.

UVFT Management Comes From Some of the Biggest Moneymakers in Health Care and Finance

UV Flu Technologies management team has a demonstrated record of success in the multi-millions with products such as the \$20 million a year Comfort Mist. They have what it takes to lead UVFT to the NASDAQ just like Genzyme and Sinovac Biotech—or straight to a buyout by a corporation like 3M.



Jack Lennon President and CEO

A true management heavyweight, Jack has been president of UV Flu Technologies since its inception in July of 2009. For the past six years he has also served as president of Chamberlain Capital Partners, a consulting company specializing in business formation and finance.

Jack is a past officer and director of Explortex Energy, Brite-Strike Tactical Illumination, GC China Turbines, and US Starcom. Among his other credentials he served as senior vice president of Janney-Montgomery Scott and Smith-Barney.



Jack holds a BSME from UMass/Amherst, with minors in Finance and Geological Engineering, and a MBA in Corporate Finance from Boston University.



Roger Nelsen, Director

Roger brings over 36 years experience in the medical equipment and health care sector to UV Flu Technologies. He has a strong track record, having served as senior vice president at Eco-Rx, Inc., a company specializing in the air purification industry and as principle of Nelsen & Associates, an independent health care sales and consulting organization.

For more than a decade Roger held senior positions with medical equipment manufacturers Retec, and Everest & Jennings. His highly successful career began more than 30 years ago where he spent numerous years within various divisions of Johnson & Johnson.

Roger Nelsen holds a B.S. in Business Administration from the University of Connecticut.



Glen Bushee, Director

Glen serves as president of Brite-Strike Tactical Illumination Products. For the past 20 years he's held senior management positions for 3P North America, and Sunbeam Corp. among others.

He was closely involved in the UVFT product design process and spent time living in China in order to oversee production which includes all phases, from design to pricing. While there he built an extensive network of industry contacts and a strong manufacturing knowledge-base.



Among his most esteemed credits is as developer of Comfort Mist—an air purifier with \$20 million in annual sales.

10 reasons to invest in UVFT

...for what could be the killer biotech buy of the year with 370% profit potential!

- 1. FDA approval has already been received**, allowing UVFT to market its product as a medical device—such approval is highly unusual for a biotech at this stage. Not to mention very few air purifiers have FDA approval. That gives UVFT a big competitive edge. *see pg. 9*
- 2. Top 5 U.S. Hospitals Put UVFT Technology to Work**—UVFT's UV-400 is already in operation at two of the most respected medical institutions: The Division of Infectious Diseases at Massachusetts General Hospital and New England Baptist Hospital. *see pg. 4*
- 3. Independent laboratory testing proves UVFT's technology works** and is 99.2% to 99.9% effective at killing bacteria on the first pass. *see pg. 8*
- 4. OSHA, the the main U.S. federal agency charged with the enforcement of safety and health legislation, is creating a moneymaking opportunity for UVFT and its shareholders.** Indoor air quality is a growing problem, creating health hazards and sick buildings. OSHA is already issuing directives to provide a healthier work environment for workers. *see pg. 5*
- 5. This year's bad flu season** is all it will take to send UVFT's share price soaring to potential highs of 370% or higher. Business and consumers are going to want the best protection available—and it won't be blue masks. *see pg. 7*
- 6. Strong buyout potential by corporate giants 3M or Honeywell** that could send share prices through the rafters. *see pg. 8*
- 7. Shares at the groundfloor entry point of just \$0.30**—this is the stage you stand to make the biggest gains—this low price still has blue sky potential.
- 8. Experienced management team**—a powerhouse team that's been with the heavyweights in health care and finance—those such as Johnson and Johnson and Janney Montgomery Scott. One key team member already successfully brought a \$20 million per year product to market! Now UVFT is about to do it again. *see pg. 10*
- 9. THREE revenue streams already in place:** the flagship Viratech UV-400, the smaller version of the UV-400, and replaceable cartridges for the units are all avenues for UVFT to generate a steady revenue stream. *see pg. 8, 9*
- 10. UVFT has the first breakthrough in the air purification market in 70 years.** Breakthroughs like that create investment opportunities of a lifetime. *see pg. 8*

Urgent Buy Alert

Company: UV Flu Technologies
Symbol: UVFT

Current share price:.....	\$0.30
3 month projection:.....	\$0.92
12 month projection:.....	\$1.41

Recommendation:
Immediate Buy

With Flu season upcoming,
NOW is the time to get in on UVFT.
Visit www.ndm1flu.com Today!

I strongly recommend you call your broker or go online today to buy shares in UVFT without delay. All of the forces are aligned for the company to experience explosive growth and increase shareholder value—and the share price—exponentially.

There is a tremendous pent up market demand for UVFT's technology and the timing is ideal to invest for strong potential gains in the coming weeks and months.

DYING FOR AN ANSWER

Hospital infections kill more people each year than AIDS, breast cancer and auto accidents combined.

Next time you check into the hospital you're going to think twice. What used to be a safe haven for people to get well has virtually become a death sentence.

As many as 1 in 10 patients that checks into a U.S. hospital acquires an infection. Nearly 2 million patients a year are infected. What's worse...

100,000 WILL DIE.

As if the toll on human lives was not enough, the costs associated with hospital-acquired bacterial infections are staggering.

The Wall Street Journal reports that **hospital acquired infections cost up to \$6.5 BILLION a year**. What's more, these highly preventable bacterial infections cost the U.S. about \$30 billion a year, according to the Center for Disease Control and Prevention.

Bacterial infections acquired during hospital stays are so widespread that 26 states have enacted laws requiring hospitals to report their infection rates.

STAPH (MRSA) Infections could propel UVFT to Super Stock Status

In 1993, fewer than 2,000 people in U.S. hospitals would contract a staph infection. By 2005, that number rose to 368,000 and in 2007 staph infections claimed 880,000 victims.

A recent nationwide study showed that patients with staph infections incur hospital costs that are more than triple the average hospital costs of other patients.

MRSA is certainly not the only bacterial infection making us sick and killing us. There are post-surgical wound infections, urinary tract infections, C. Difficile, influenza, pneumonia—the list goes on and on.

Our hospitals want a device that wipes out and kills these harmful bacteria and they will pay to get it. UVFT has the next generation—a revolution in air purification and health care that could dramatically improve every U.S. hospitals bottomline and our health.

Using UVFT's FDA-approved Viratech UV-400, hospitals can begin obliterating bacteria and airborne pathogens on-the-spot with a 99% kill rate on every pass through. I have not come across even one other product that remotely comes close.

Buy up as many shares of UVFT as you can then sit back and watch it rocket from \$0.30 to \$0.92 then \$1.41 inside of 12 months.



Contact UV Flu Technologies Today!
Visit www.ndm1flu.com
or Call Investor Relations at 1-888-355-8838

Top 5 U.S. Hospitals Put UVFT Technology to Work

Just Announced: UVFT's UV-400 is Already in Operation at Two of the Most Respected Medical institutions: The Division of Infectious Diseases at Massachusetts General Hospital and New England Baptist Hospital.

Feedback has been extremely favorable with hospital staff reporting noticeably less coughing and fewer respiratory symptoms—within the first week of operation.

Sales of UVFT's FDA approved Viratech UV-400 are projected to

increase dramatically as more units are put in place at more hospitals nationwide. The lucky ones won't just be the hospitals and hospital patients whose lives are saved—it'll be the investors who got in on the groundfloor of UVFT.

Remember, this is a strong young biotech with a first-ever technology to market. UVFT's product has FDA approval as a medical device and proven in independent lab tests to kill more than 99% of bacteria—on the first pass and every pass.

This advancement is revolutionary and sure to send UVFT's share price soaring a potential **370%**!

Powerful names in health care and sports are buying up UVFT's "killer" technology

Although UVFT's flagship product is just launching, this leading young biotech **already has substantial orders from various key market sectors.**

Organizations like the well-respected Massachusetts General Hospital (Harvard's teaching hospital and Top 5 Hospital in USA), New England Baptist Hospital and New England Sports Sales, a major specialty sporting equipment distributor, have placed orders. UVFT's growing client list includes:



Expect to see vigorous sales especially moving into the fall with flu season back on the radar screen. We'll be looking for announcements of new clients and orders on a regular basis.

Not a one trick pony

In order for a company to make it to my pick list, it has to have multiple revenue streams. We saw that with the replaceable filter the UV-400 unit uses, there is already a second revenue stream. But that's not all...

I just got word that UVFT is ready to ship to commercial accounts, the company's next product—a smaller, lighter and economical version will be designated as the UV-200 and will be designed with the needs of the health-conscious homeowner in mind.

With those three revenue streams in place, I am confident that the share price could shoot from \$0.30 to \$1.41 within 12 months.



NEWS FLASH!

UVFT receives FDA approval for Class II medical device

FDA approval is not easy to obtain. Like most government agencies, there are reams of red tape and approvals can take a protracted amount of time.

Just to develop the technology took 10 years and \$5 million in R&D and the FDA review alone took close to a year.

If you're not familiar with it, the FDA conducts a painstaking review that includes reviewing the efficacy of the technology, all independent lab results as well as product safety.

Their extensive review ensures the product complies with all company claims.

With the FDA approval, UVFT now has far greater credibility in the marketplace.

Here's something else you need to know that makes holding shares in UVFT even MORE valuable: Few air purification products are listed by the FDA as a Class II medical device. Only the best of the best meet

the most stringent standards. It is that FDA approval that will propel UVFT to multi-millions of dollars in sales and revenue—and that means the shareholder value just skyrocketed.

With approval secured, the company is already seeking additional FDA approvals in the air purification market for other technologies. As you will see, UVFT is no one trick pony.

Shareholders can take that to the bank as the profits start rolling in.



Profit-building patented technology with \$5 million in Research and Development behind it

Ten years and \$5 million dollars were spent developing the technology and only then was UVFT's flagship product, the Viratech UV-400, born.

UV Flu Technologies went through a painstaking process to ensure all the bases were covered, including countless hours in engineering and design, testing and tooling, retooling, conducting focus groups as well as applying for patents and FDA approval.

The company has filed 43 patent claims covering every conceivable nook and cranny of the device.



Unlike many products and technologies on the market, UVFT's have been well conceived, well thought out and well executed. It simply can't fall flat. In fact, it has a...

Continuous revenue stream built right in

UVFT management thought of everything—including how to build additional revenue streams. Besides fetching \$1,350 for each unit, UV Flu Technologies also created the UV-400 with a replaceable cartridge. Throughout the product life-cycle, UVFT can continue to pull down revenue from that cartridge.


Independent EPA and FDA-Certified lab testing prove it: UVFT's Viratech UV-400 is a Winner!

Not only did UVFT receive coveted FDA approval, they also had tests conducted by an independent EPA and FDA-certified laboratory. These independent tests confirm that the system captures and kills airborne bacteria at rates from 99.2% to 99.9% on a first-pass basis.

In actual operation, multiple passes through the unit produce average removal rates that far exceed 99.2%.

UVFT has everything in place to storm the market with their breakthrough technology—and bring double even TRIPLE-DIGIT gains to shareholders in the coming weeks.

Here's how UVFT's technology works:



Another bonus: after 12 months of continuous operation the sealed cartridge can be discarded with regular trash. There is no need to dispose of it as medical waste. Plus, there's nothing complicated about it. Users simply plug it in and turn it on.

Takeover Target: UVFT



Companies like 3M and Honeywell are looking to increase their presence in the biotech market.

Contact UV Flu Technologies Today!
Visit www.ndm1flu.com
or Call Investor Relations at 1-888-355-8838



ENVIRONMENTAL PROTECTION AGENCY WARNS: "Indoor air quality poses a greater threat than outdoor air"

Take a look at the rise of chronic respiratory diseases like asthma, for example, and it's easy to understand why the EPA has proclaimed indoor air quality a major threat.

In 1990, there were 10 million Americans suffering with asthma. Today that number stands at an eye-popping 20 million—DOUBLE in the past 20 years. What's worse, asthma is projected to DOUBLE again over the next 20 years.

What's suffocating our ability to breathe free and clear? Bacteria, molds and toxins as well as exposure to chemicals in cleaning agents, pollution, second hand smoke and more—all free floating through the air with nothing to stop them.

UVFT scientists, researchers and engineers saw a tremendous market opportunity to develop an air purification system that would not filter these poisons and toxins but eradicate them—kill them dead.

Indoor air quality is so poor that OSHA is Stepping In.

When the Occupational Safety and Health Administration steps in, businesses like UVFT stand to make a lot of money

While OSHA has not yet called for a formal regulation, it is in the process of calling for new standards in airborne infectious disease protection for health care workers. OSHA's recent enforcement directive requires that health care employers protect workers from tuberculosis, SARS, H1N1 and other influenza. For shareholders in UVFT this is huge news. Anytime OSHA issues a directive or anytime a new federal regulation is passed, that spells a tremendous moneymaking opportunity for companies that

have to provide products and services to companies that must comply—and for its investors.

Using UVFT's breakthrough Viratech UV-400 the millions of workplaces and sick buildings around the country can better protect their workers—and their bottomline—from airborne infectious diseases and bacteria.

I'm convinced that UVFT is the next Big Money Winner

And then... there's the flu

Remember the H1N1 pandemic last year? A staggering \$1 BILLION was spent on H1N1 vaccine development with \$4.3 BILLION spent on the response. Who could forget the fear over Avian (Bird) Flu or SARS a few years ago? Even seasonal flu kills.

Put it altogether and think of the potential for UVFT's technology to revolutionize the industry. Influenza, bacterial infections, chronic respiratory diseases—the market for

President's Quote

"The ViraTech UV-400 is one of the few Indoor Air Quality ('IAQ') products in the world cleared by the FDA for use as a medical device, and is designed specifically to kill over 99% of bacteria with each pass, and we believe that with all of the recent media discussion on air quality, that there is huge potential and need for this superior, maintenance-free and highly effective product."

~ Jack Lennon, President of UV Flu Technologies

UVFT technology is mind boggling.



Now's The Time To Buy Shares in UVFT

for just pennies on the dollar. Based on everything I know about UVFT, 370% gains over the coming weeks is just the beginning!

THIS YEAR'S KILLER FLU COULD

TURN YOU INTO A MILLIONAIRE

I've been hiding something from you...

A force so big, so powerful it could send UVFT's share price into the DOUBLE DIGITS making you rich.

Last year the H1N1 virus created near hysteria. Millions were petrified of contracting it. WHO declared it a pandemic, estimating 30,000 to as many as 90,000 deaths in the U.S. alone—9 million worldwide.

Governments sprung into action, spending money as fast as it was being printed. Vaccines for H1N1 were given out as fast as they could make them. A cool \$1 billion got the H1N1 vaccine started and when all was said and done the vaccine response cost a staggering \$4.3 billion. Makers of the vaccine saw sales reach \$3.3 billion. Sales of Tamiflu, the anti-viral prescription drug recommended for influenza, jumped by \$1.74 billion in 2009. This year sales worldwide could reach a stunning \$10 billion.

You couldn't turn on the News without hearing about a possible new case of the Swine Flu—or about how it was spreading from city to city, county to county, state to state, country to country.

All of these numbers prove one thing:

People, business and government are concerned about bacteria and germs and the spread of a poten-

tially killer flu. Hand washing, sanitizers, masks... we'll go to great lengths to avoid the flu and harmful bacteria.

My point to you as an investor is this...

Chances are, you haven't heard of it yet, but NDM-1 is setting up to be the biggest threat this flu season. Born from antibiotic-resistant bacteria, NDM-1 has emerged stronger and more powerful than H1N1—and is already making its way across the ocean.

How bad could it be if you haven't even heard of it yet? Don't underestimate NDM-1 just because the media hasn't gone into a frenzy. Researchers at the journal of The Lancet of Infectious Diseases issued

a grave warning about this new gene that enables bacteria to put on a body of armor when it comes to virtually all antibiotics.

Here's how it works: a new superbug bacteria is producing an enzyme called NDM-1 (New Delhi

metallo-beta-lactamase) which has the power to fend off even the most powerful antibiotics. NDM-1 can jump from one strain of bacteria to another, including Salmonella and E-coli.

Should NDM-1 piggyback with other antibiotic resistant bacteria, it could cause dangerous infec-

tions that can't be treated. So far, the new superbug has been pinpointed in the UK, Canada, Sweden, USA, Australia, the Netherlands as well as in India, where it started, and Pakistan. Having just come out of a worldwide H1N1 pandemic, news of NDM-1 is bad for the public but is creating a magnificent money making opportunity for UVFT shareholders.

What do you think will happen when news gets out that...

UVFT's technology can annihilate the NDM-1 bacteria before it can reach 'Superbug' status!

This is the silver bullet every company looks for—an answer to extinguishing bacteria before it transitions to superbug status no antibiotic can kill off.

When NDM-1 makes its way into the U.S., just in time for flu season, the response will be far greater than it was for H1N1. Since UVFT's technology is FDA approved to kill bacteria, sales of UVFT's Viratech UV-400 could blow through the roof.

In case you don't remember, BILLIONS were spent on H1N1. The world went crazy. Fear and panic spread rapidly. Obama declared a national emergency and the government went into a frenzy, spending ONE BILLION DOLLARS to get the vaccine started. In the end, more than \$4.3 billion was spent on the response.

NDM-1 is far worse. There is NO vaccine. There are NO antibiotics to treat it. If multi billions of dollars were spent on H1N1, imagine how much more will be spent on responding to and preparing for NDM-1.

UVFT has the technology NOW to kill the NDM-1 bacteria before it can turn it into one of the most deadly super bugs ever known to man.

Any one holding shares in UVFT could stand to make an absolute fortune!

“The potential for wider international spread of producers and for NDM-1 encoding plasmids to become endemic worldwide, are clear and frightening.”

“Harmful bacteria continues to explode in our hospitals, schools workplaces”
--that's good news for UVFT shareholders

Talk to your advisor today about



Buy UVFT Now for the Most Staggering Gains!

Contact UV Flu Technologies Today!
 Visit www.ndm1flu.com
 or Call Investor Relations at 1-888-355-8838

There were three pandemics in the 20th century alone—the Spanish Flu, Asian Flu and Hong Kong Flu contributing to more than 600,000 deaths in the U.S. and millions worldwide.

All we need is one more pandemic or a bad bout of seasonal flu and sales of UVFT will blow through the rafters. You know it will happen—there's a flu season every year. Not to mention viruses like H1N1 are mutating.

1918
Spanish Flu
 20-100 million people die

1957
Asian Flu
 1-1.5 million people die

1968
Hong Kong Flu
 1 million people die

2002
SARS
 37 Countries Infected

2009
H1N1 (Swine Flu)
 \$4.3Billion in Vaccine Response

2010 - 2011
NDM-1 Superbug
 ????????????????